Low-Dose Naltrexone and Prolactin:What Clinicians Should Know About an Emerging Question
Yoon Hang Kim, MD, MPH
Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician
Introduction
As low-dose naltrexone (LDN) prescribing grows across integrative, functional, and conventional medicine settings, clinicians are occasionally encountering an unexpected laboratory finding: a mildly elevated serum prolactin in a client taking LDN. This raises an important clinical question — can LDN cause hyperprolactinemia?
The short answer is that LDN could plausibly contribute to a small, transient prolactin increase, but the available evidence is indirect. It derives almost entirely from studies of standard-dose (50 mg) or acute-challenge naltrexone protocols rather than chronic low-dose regimens (typically 0.5–4.5 mg nightly). Sustained, clinically meaningful hyperprolactinemia from LDN has not been convincingly demonstrated.
The Neuroendocrine Mechanism: Why This Is More Complex Than It Appears
To understand the relationship between naltrexone and prolactin, it helps to revisit how prolactin secretion is regulated. Prolactin release from anterior pituitary lactotrophs is tonically inhibited by dopamine, which reaches the pituitary via the tuberoinfundibular dopaminergic (TIDA) pathway originating in the arcuate nucleus of the hypothalamus.1
Endogenous opioid peptides — particularly those acting at mu- and kappa-opioid receptors — reduce TIDA dopamine output. Because dopamine is the principal prolactin-inhibiting factor, opioid agonists (including heroin, morphine, and endogenous beta-endorphin) raise prolactin levels by dampening this dopaminergic brake.1,2 This is why opioid-dependent individuals frequently develop hyperprolactinemia.
Here is where the story becomes counterintuitive. One might predict that an opioid antagonist like naltrexone would disinhibit TIDA neurons, increase dopamine delivery to lactotrophs, and thereby decrease prolactin. Indeed, several older studies in both humans and nonhuman primates reported either no change or a decrease in prolactin following opioid antagonist administration.2,3,4
However, more recent controlled studies have documented a prolactin increase following both naltrexone and the structurally related antagonist nalmefene.5,6,7 This paradox is now attributed to a mechanism that was not appreciated in the earlier literature: naltrexone and nalmefene appear to function not as pure antagonists across all opioid receptor subtypes, but rather as partial agonists at the kappa-opioid receptor.5,6
Kappa-opioid receptor agonism inhibits TIDA dopamine neurons, which reduces the tonic dopaminergic restraint on lactotrophs and allows prolactin to rise.5,8 In vitro binding studies have confirmed that nalmefene is a full antagonist at mu-opioid receptors but demonstrates partial agonist properties at kappa-opioid receptors, with approximately 25% intrinsic efficacy.5,9 Naltrexone appears to have similar but less well-characterized kappa partial agonist activity.6,7,10
Sex Differences and Menstrual Cycle Phase
The prolactin response to naltrexone is not uniform across populations. In a carefully designed randomized, placebo-controlled study, Roche and King (2015) administered 50 mg of naltrexone to 70 healthy volunteers — 46 women and 24 men. Women were randomized to complete sessions in either the early follicular or the luteal phase of the menstrual cycle.7
In both early follicular and luteal women, naltrexone significantly increased serum prolactin levels compared to placebo. The increase was significantly greater in luteal-phase women than in early follicular women. Notably, men showed no significant prolactin response to naltrexone.7 These findings are consistent with earlier work by Cetel, Quigley, and Yen (1985), who demonstrated that naloxone-induced prolactin secretion in women was dependent on prevailing levels of estradiol and progesterone, occurring in the late follicular and midluteal phases but not in hypogonadal women or the early follicular phase.11
Conversely, Ellingboe, Mendelson, and Kuehnle (1980) found no evidence that a single dose of naltrexone affected basal prolactin levels in men with a history of heroin addiction.3
What About Chronic Dosing? The Evidence Gap for LDN
The studies cited above all used standard-dose naltrexone (50 mg) or intravenous naloxone challenge — doses that produce near-complete opioid receptor occupancy for 24 hours or more. LDN, by contrast, uses doses 10- to 100-fold lower (0.5–4.5 mg), producing a transient receptor blockade lasting approximately four hours before receptor sensitivity is restored.12,13
This distinction matters because LDN's proposed therapeutic mechanism centers on the rebound phase after the brief blockade — a period of enhanced endogenous opioid signaling and receptor upregulation.12 Whether the brief window of kappa partial agonism at these low doses is sufficient to meaningfully shift prolactin remains unknown.
One directly relevant study suggests the effect may not persist with chronic dosing. Graves and colleagues (1997) administered naltrexone 50 mg daily throughout the follicular phase (cycle days 2–14) in a randomized, double-blind, crossover design and measured prolactin during the subsequent midluteal phase. Midluteal prolactin was actually lower in naltrexone cycles compared with placebo cycles (12.6 ± 3.3 vs. 15.4 ± 3.0 μg/L; P < 0.05).14 The authors interpreted this as suggesting that withdrawal of chronic opioid blockade may enhance opioid effects on prolactin during the subsequent phase — but the key finding for our purposes is that chronic naltrexone administration did not cause sustained prolactin elevation.
To date, no published clinical trials have systematically measured prolactin levels during chronic LDN therapy. This represents a genuine evidence gap.
Clinical Framing: LDN Is Not a Classic Hyperprolactinemia Culprit
It is important to emphasize that LDN does not belong in the same pharmacologic category as the well-established medication-induced causes of hyperprolactinemia. Dopamine receptor antagonists — including typical and atypical antipsychotics (haloperidol, risperidone, olanzapine), antiemetics (metoclopramide, prochlorperazine, domperidone), and certain prokinetics — directly block the D2 receptor on lactotrophs and can produce prolactin elevations that are dramatic (often > 100 ng/mL) and sustained.15
The mechanism by which naltrexone might raise prolactin — indirect kappa-opioid partial agonism affecting TIDA dopamine tone — is far less potent and likely transient. In a client with an elevated prolactin, LDN should be considered a possible confounder rather than the presumed explanation.
Practical Approach to an Elevated Prolactin in a Client Taking LDN
1. Repeat the measurement under optimal conditions. Obtain a fasting, morning prolactin level. Ideally, the client should avoid vigorous exercise, breast or chest-wall stimulation, sexual activity, and venipuncture-related stress in the hours prior to the draw.15
2. Screen for macroprolactin. If the elevation is modest (typically < 100 ng/mL) and the clinical picture is discordant — no galactorrhea, no menstrual disruption — request macroprolactin testing. Macroprolactinemia accounts for a meaningful percentage of unexplained mild hyperprolactinemia and is a benign finding.15,16
3. Evaluate for established etiologies. The differential should include pregnancy and lactation, primary hypothyroidism, renal insufficiency, dopamine-blocking medications (including some that clients may not think to mention, such as metoclopramide or prochlorperazine), estrogen-containing preparations, chest-wall pathology, and pituitary adenoma.15
4. Consider timing relative to LDN dosing. If the prescribing clinician wishes to evaluate whether LDN is contributing, the blood draw can be scheduled at a consistent interval from the last dose — or repeated after a temporary LDN hold (typically 5–7 days). This is not a standardized protocol, but it offers useful clinical information.
5. Pursue a standard workup for persistent or symptomatic elevation. Any client with persistent hyperprolactinemia — particularly when accompanied by galactorrhea, oligo- or amenorrhea, infertility, hypogonadal symptoms, new headache, or visual field changes — warrants a complete workup including pituitary MRI, regardless of LDN use.
Important: This article is for educational purposes and does not constitute medical advice. An elevated prolactin level should be evaluated in consultation with a qualified healthcare provider who can consider the full clinical context.
Bottom Line
LDN could plausibly contribute to an acute, modest prolactin increase — most likely through kappa-opioid receptor partial agonism affecting tuberoinfundibular dopamine — but sustained, clinically significant hyperprolactinemia from LDN has not been demonstrated. For a persistently abnormal prolactin result, the standard etiologic workup should take precedence. LDN is best treated as one variable to test rather than the presumed cause.
References
1. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523-1631.
2. Mello NK, Mendelson JH, Bree MP, Skupny A. Naltrexone effects on pituitary and gonadal hormones in male and female rhesus monkeys. Pharmacol Biochem Behav. 1988;31(3):683-691.
3. Ellingboe J, Mendelson JH, Kuehnle JC. Effects of heroin and naltrexone on plasma prolactin levels in man. Pharmacol Biochem Behav. 1980;12(1):163-165.
4. Yen SSC, Quigley ME, Reid RL, Ropert JF, Cetel NS. Neuroendocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secretion. Am J Obstet Gynecol. 1985;152(4):485-493.
5. Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology. 2005;30(12):2254-2262.
6. Butelman ER, Fry RS, Kimani R, Reed B, Kreek MJ. Neuroendocrine effects of naltrexone versus nalmefene in humans. Hum Psychopharmacol. 2020;35(2):e2726.
7. Roche DJO, King AC. Sex differences in acute hormonal and subjective response to naltrexone: the impact of menstrual cycle phase. Psychoneuroendocrinology. 2015;52:59-71.
8. Kreek MJ, Schluger J, Borg L, Gunduz M, Ho A. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther. 1999;288(1):260-269.
9. Wentland MP, Lou R, Lu Q, et al. Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009;19(8):2289-2294.
10. Schacht L, Goedecke L, Gajdos Z, et al. The influence of opioid blockage on the sexual response cycle: a randomized placebo-controlled experiment with relevance for the treatment of compulsive sexual behavior disorder. Psychoneuroendocrinology. 2023;147:105962.
11. Cetel NS, Quigley ME, Yen SSC. Naloxone-induced prolactin secretion in women: evidence against a direct prolactin stimulatory effect of endogenous opioids. J Clin Endocrinol Metab. 1985;60(1):191-196.
12. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459.
13. Bateman Horne Center. Low Dose Naltrexone (LDN). Clinical Guidance Document. September 2024.
14. Graves GR, Kennedy TG, Weick RF, Casper RF. Suppression of luteal phase, but not midcycle, prolactin levels by chronic follicular phase opiate antagonism. Fertil Steril. 1997;68(6):1017-1022.
15. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.
16. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab. 2005;90(7):3927-3932.
About Dr. Kim
Dr. Yoon Hang "John" Kim is board-certified with over 20 years of experience in integrative and functional medicine. He completed his fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. Dr. Kim is the author of three books and over 20 articles on integrative medicine topics.
Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com
